These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 22592842)

  • 1. Oral anticoagulation and VKORC1 polymorphism in patients with a mechanical heart prosthesis: a 6-year follow-up.
    Giansante C; Fiotti N; Altamura N; Pitacco P; Consoloni L; Scardi S; Mazzone C; Grassi G; Pandullo C; Di Lenarda A
    J Thromb Thrombolysis; 2012 Nov; 34(4):506-12. PubMed ID: 22592842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy.
    Kovac MK; Maslac AR; Rakicevic LB; Radojkovic DP
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):558-63. PubMed ID: 20581661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanical heart valve recipients: anticoagulation in patients with genetic variations of phenprocoumon metabolism.
    Brehm K; Schack J; Heilmann C; Blanke P; Geissler HJ; Beyersdorf F
    Eur J Cardiothorac Surg; 2013 Aug; 44(2):309-14; discussion 314-5. PubMed ID: 23423913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A vitamin K epoxide reductase-oxidase complex gene polymorphism (-1639G>A) and interindividual variability in the dose-effect of vitamin K antagonists.
    Stepien E; Branicka A; Ciesla-Dul M; Undas A
    J Appl Genet; 2009; 50(4):399-403. PubMed ID: 19875892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
    Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
    Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Polymorphisms of genes CYP2C9 and VKORC1 in patients with venous thromboembolic complications in Moscow population: effects on stability of anticoagulant therapy and frequency of hemorrhage].
    Vorob'eva NM; Panchenko EP; Dobrovol'skiĭ AB; Titaeva EV; Khasanova ZB; Konovalova NV; Postnov AIu; Kirienko AI
    Ter Arkh; 2011; 83(6):59-65. PubMed ID: 21786578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In pediatric patients, age has more impact on dosing of vitamin K antagonists than VKORC1 or CYP2C9 genotypes.
    Nowak-Göttl U; Dietrich K; Schaffranek D; Eldin NS; Yasui Y; Geisen C; Mitchell LG
    Blood; 2010 Dec; 116(26):6101-5. PubMed ID: 20833980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of gene polymorphisms with the risk of warfarin bleeding complications at therapeutic INR in patients with mechanical cardiac valves.
    An SH; Lee KE; Chang BC; Gwak HS
    J Clin Pharm Ther; 2014 Jun; 39(3):314-8. PubMed ID: 24602049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The c.-1639g > A polymorphism of the VKORC1 gene and his influence on the therapeutic response during oral anticoagulants use].
    Kovac M; Rakićević L; Maslać A; Radojković D
    Vojnosanit Pregl; 2009 Aug; 66(8):617-21. PubMed ID: 19780415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contribution of age, body weight, and CYP2C9 and VKORC1 genotype to the anticoagulant response to warfarin: proposal for a new dosing regimen in Chinese patients.
    Miao L; Yang J; Huang C; Shen Z
    Eur J Clin Pharmacol; 2007 Dec; 63(12):1135-41. PubMed ID: 17899045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Value of VKORC1 (-1639G>A) rs9923231 genotyping in predicting warfarin dose: A replication study in South Indian population.
    Harikrishnan S; Koshy L; Subramanian R; Sanjay G; Vineeth CP; Nair AJ; Nair GM; Sudhakaran PR
    Indian Heart J; 2018 Dec; 70 Suppl 3(Suppl 3):S110-S115. PubMed ID: 30595241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
    Lund K; Gaffney D; Spooner R; Etherington AM; Tansey P; Tait RC
    Br J Haematol; 2012 Jul; 158(2):256-261. PubMed ID: 22571356
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetic tests could be helpful in predicting of VKA maintenance dose in elderly patients at treatment initiation.
    Kovac MK; Rakicevic LB; Kusic-Tisma JS; Radojkovic DP
    J Thromb Thrombolysis; 2013 Jan; 35(1):90-4. PubMed ID: 22763922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study.
    Brunner-Ziegler S; Jilma B; Magirr D; Sunder-Plassmann R; Giurgea GA; Hammer A; Margeta C; Brunner M; Koppensteiner R; Mannhalter C
    Br J Haematol; 2014 Nov; 167(4):547-53. PubMed ID: 25142093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variations of phenprocoumon metabolism in patients with ventricular assist devices.
    Brehm K; Krumnau O; Heilmann C; Beyersdorf F
    Eur J Cardiothorac Surg; 2016 Aug; 50(2):275-80. PubMed ID: 26984978
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
    Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
    Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Warfarin dose requirements with different genotypes of CYP2C9 and VKORC1 for patients with atrial fibrillation and valve replacement.
    Chen W; Wu L; Liu X; Shen Y; Liang Y; Zhu J; Tan H; Yang Y; Liu Q; Wang M; Liu L; Wang X
    Int J Clin Pharmacol Ther; 2017 Feb; 55(2):126-132. PubMed ID: 27117036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VKORC1 polymorphisms and warfarin maintenance dose in population of Sakha (Yakuts).
    Chertovskikh YV; Malova EU; Maksimova NR; Popova NV; Sychev DA
    Int J Risk Saf Med; 2015; 27 Suppl 1():S17-8. PubMed ID: 26639691
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VKORC1 variant genotypes influence warfarin response in patients undergoing total joint arthroplasty: a pilot study.
    González Della Valle A; Khakharia S; Glueck CJ; Taveras N; Wang P; Fontaine RN; Salvati EA
    Clin Orthop Relat Res; 2009 Jul; 467(7):1773-80. PubMed ID: 19034590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients.
    Misasi S; Martini G; Paoletti O; Calza S; Scovoli G; Marengoni A; Testa S; Caimi L; Marchina E
    Medicine (Baltimore); 2016 Dec; 95(52):e5451. PubMed ID: 28033245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.